Literature DB >> 16870765

In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.

Kerin L Tyrrell1, Diane M Citron, Yumi A Warren, Helen T Fernandez, C Vreni Merriam, Ellie J C Goldstein.   

Abstract

Daptomycin has in vitro activity against gram-positive anaerobic bacteria, although limited numbers of species have been tested. We studied the in vitro activities of daptomycin, vancomycin, and penicillin against more than 100 strains each of Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Daptomycin Etest MICs and results from time-kill studies were determined for selected strains. For 392 of 421 strains (93%), daptomycin was inhibitory at < or =1 microg/ml, including 15 of 16 strains of C. difficile with elevated linezolid MICs of 8 and 16 microg/ml, all 32 strains with moxifloxacin MICs of > or =4 microg/ml, and all 16 strains resistant to clindamycin. Daptomycin MICs were also < or =1 microg/ml for all 16 F. magna strains resistant to clindamycin and all 32 strains resistant to tetracycline. Only one strain, a C. perfringens strain, had a MIC of >2 microg/ml to daptomycin. Eighty-five and 92.5% of the Etest MICs were within 1 dilution of the agar dilution method for all drugs at 24 and 48 h, respectively. In time-kill studies, a C. difficile strain was inhibited by both daptomycin and vancomycin at 1, 2, 4, 8, and 24 h; colony counts were decreased by 2.3 to 2.9 log at 24 h. Vancomycin was not bactericidal for C. perfringens; however, daptomycin showed bactericidal activity as early as 1 h at four and eight times the MIC and at 2 and 4 h at two and four times the MIC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870765      PMCID: PMC1538685          DOI: 10.1128/AAC.00357-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  In vitro bactericidal activity of daptomycin against staphylococci.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

2.  Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.

Authors:  R Wise; J M Andrews; J P Ashby
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

3.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.

Authors:  Daniel J Skiest
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.

Authors:  A W Chow; N Cheng
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.

Authors:  Jeff Alder; Tongchaun Li; Donghui Yu; Larry Morton; Jared Silverman; Xi-Xian Zhang; Ian Critchley; Grace Thorne
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Authors:  Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein
Journal:  Clin Infect Dis       Date:  2004-05-20       Impact factor: 9.079

9.  In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.

Authors:  D M Citron; C V Merriam; K L Tyrrell; Y A Warren; H Fernandez; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Comparative activity of LY146032 against anaerobic cocci.

Authors:  D Greenwood; J Palfreyman
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

View more
  14 in total

1.  Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.

Authors:  Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jeng Teng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.

Authors:  Carmela T M Mascio; Lawrence I Mortin; Karen T Howland; Andrew D G Van Praagh; Shuxin Zhang; Anu Arya; Cun Lan Chuong; Chunfeng Kang; Tongchuan Li; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.

Authors:  Brandon J Webb; Aruna Subramanian; Bert Lopansri; Bruce Goodman; Peter Bjorn Jones; Jeffrey Ferraro; Edward Stenehjem; Samuel M Brown
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.

Authors:  Hannah M Adams; Xiang Li; Carmela Mascio; Laurent Chesnel; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

5.  Antimicrobial susceptibility of Propionibacterium acnes isolates from shoulder surgery.

Authors:  John K Crane; Donald W Hohman; Scott R Nodzo; Thomas R Duquin
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

6.  Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4.

Authors:  Christina S Hölzel; Katrin S Harms; Karin Schwaiger; Johann Bauer
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

7.  Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.

Authors:  Efi Kokkotou; Alan C Moss; Athanasios Michos; Daniel Espinoza; Jeffrey W Cloud; Nasima Mustafa; Michael O'Brien; Charalabos Pothoulakis; Ciarán P Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

8.  Acne is not associated with yet-uncultured bacteria.

Authors:  M Bek-Thomsen; H B Lomholt; M Kilian
Journal:  J Clin Microbiol       Date:  2008-08-20       Impact factor: 5.948

Review 9.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.